Jump to main content
Jump to site search

Volume 177, 2015
Previous Article Next Article

Pluronic copolymer encapsulated SCR7 as a potential anticancer agent

Author affiliations

Abstract

Nonhomologous end joining (NHEJ) of DNA double strand breaks (DSBs) inside cells can be selectively inhibited by 5,6-bis-(benzylideneamino)-2-mercaptopyrimidin-4-ol (SCR7) which possesses anticancer properties. The hydrophobicity of SCR7 decreases its bioavailability which is a major setback in the utilization of this compound as a therapeutic agent. In order to circumvent the drawback of SCR7, we prepared a polymer encapsulated form of SCR7. The physical interaction of SCR7 and Pluronic® copolymer is evident from different analytical techniques. The in vitro cytotoxicity of the drug formulations is established using the MTT assay.

Back to tab navigation

Publication details

The article was received on 15 Sep 2014, accepted on 04 Nov 2014 and first published on 21 Jan 2015


Article type: Paper
DOI: 10.1039/C4FD00176A
Faraday Discuss., 2015,177, 155-161

  •   Request permissions

    Pluronic copolymer encapsulated SCR7 as a potential anticancer agent

    F. John, J. George, M. Srivastava, P. A. Hassan, V. K. Aswal, Subhas. S. Karki and Sathees. C. Raghavan, Faraday Discuss., 2015, 177, 155
    DOI: 10.1039/C4FD00176A

Search articles by author

Spotlight

Advertisements